Molecular detection of genetic alterations in the serum of colorectal cancer patients

Kenji Hibi, C. Rahj Robinson, Susan Booker, Li Wu, Stanley R. Hamilton, David Sidransky, Jin Jen

Research output: Contribution to journalArticle

218 Citations (Scopus)

Abstract

We have searched for the presence of genetic alterations in serum DNA obtained from 44 colorectal cancer patients. Microsatellite analysis using highly polymorphic markers revealed loss of heterozygosity and/or microsatellite instability in 35 of 44 (80%) primary tumors. No alterations were detected in the paired serum DNA. We next used an oligonucleotide- mediated mismatch ligation assay to detect tumor specific gene mutations in the serum. Among the 16 cases with a K-ras gene mutation in the tumor, the same mutation was detected in three paired serum samples. In the 10 cases with a p53 mutation in the tumor, the identical mutation was detected in seven corresponding serum samples. Comparison of the molecular analysis with clinical diagnosis of these patients revealed that none of the seven Dukes' stage B patients with a K-ras mutation in their tumors demonstrated a mutation in the serum. In contrast, five of seven stage B patients with a p53 mutation in the tumor demonstrated a mutation in the paired serum (P = 0.01, Fisher's exact test). Taken together, either a K-ras or p53 mutation was detected in the serum in 40% of the 25 patients (95% confidence interval, 21- 61%), whose primary tumors contained a mutation and in 23% of the 44 patients (95% confidence interval, 12-38%) with colorectal cancer. The frequent detection of p53 mutation in the serum of patients with early stage tumors suggests a possible use of this approach for clinical prognosis and cancer monitoring of colorectal cancer patients.

Original languageEnglish (US)
Pages (from-to)1405-1407
Number of pages3
JournalCancer Research
Volume58
Issue number7
StatePublished - Apr 1 1998
Externally publishedYes

Fingerprint

Molecular Biology
Colorectal Neoplasms
Mutation
Serum
Neoplasms
Confidence Intervals
Microsatellite Instability
ras Genes
Loss of Heterozygosity
DNA
Oligonucleotides
Microsatellite Repeats
Ligation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hibi, K., Robinson, C. R., Booker, S., Wu, L., Hamilton, S. R., Sidransky, D., & Jen, J. (1998). Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Research, 58(7), 1405-1407.

Molecular detection of genetic alterations in the serum of colorectal cancer patients. / Hibi, Kenji; Robinson, C. Rahj; Booker, Susan; Wu, Li; Hamilton, Stanley R.; Sidransky, David; Jen, Jin.

In: Cancer Research, Vol. 58, No. 7, 01.04.1998, p. 1405-1407.

Research output: Contribution to journalArticle

Hibi, K, Robinson, CR, Booker, S, Wu, L, Hamilton, SR, Sidransky, D & Jen, J 1998, 'Molecular detection of genetic alterations in the serum of colorectal cancer patients', Cancer Research, vol. 58, no. 7, pp. 1405-1407.
Hibi K, Robinson CR, Booker S, Wu L, Hamilton SR, Sidransky D et al. Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Research. 1998 Apr 1;58(7):1405-1407.
Hibi, Kenji ; Robinson, C. Rahj ; Booker, Susan ; Wu, Li ; Hamilton, Stanley R. ; Sidransky, David ; Jen, Jin. / Molecular detection of genetic alterations in the serum of colorectal cancer patients. In: Cancer Research. 1998 ; Vol. 58, No. 7. pp. 1405-1407.
@article{a5d4d2bf88cd4edca1ed5ea89304e614,
title = "Molecular detection of genetic alterations in the serum of colorectal cancer patients",
abstract = "We have searched for the presence of genetic alterations in serum DNA obtained from 44 colorectal cancer patients. Microsatellite analysis using highly polymorphic markers revealed loss of heterozygosity and/or microsatellite instability in 35 of 44 (80{\%}) primary tumors. No alterations were detected in the paired serum DNA. We next used an oligonucleotide- mediated mismatch ligation assay to detect tumor specific gene mutations in the serum. Among the 16 cases with a K-ras gene mutation in the tumor, the same mutation was detected in three paired serum samples. In the 10 cases with a p53 mutation in the tumor, the identical mutation was detected in seven corresponding serum samples. Comparison of the molecular analysis with clinical diagnosis of these patients revealed that none of the seven Dukes' stage B patients with a K-ras mutation in their tumors demonstrated a mutation in the serum. In contrast, five of seven stage B patients with a p53 mutation in the tumor demonstrated a mutation in the paired serum (P = 0.01, Fisher's exact test). Taken together, either a K-ras or p53 mutation was detected in the serum in 40{\%} of the 25 patients (95{\%} confidence interval, 21- 61{\%}), whose primary tumors contained a mutation and in 23{\%} of the 44 patients (95{\%} confidence interval, 12-38{\%}) with colorectal cancer. The frequent detection of p53 mutation in the serum of patients with early stage tumors suggests a possible use of this approach for clinical prognosis and cancer monitoring of colorectal cancer patients.",
author = "Kenji Hibi and Robinson, {C. Rahj} and Susan Booker and Li Wu and Hamilton, {Stanley R.} and David Sidransky and Jin Jen",
year = "1998",
month = "4",
day = "1",
language = "English (US)",
volume = "58",
pages = "1405--1407",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Molecular detection of genetic alterations in the serum of colorectal cancer patients

AU - Hibi, Kenji

AU - Robinson, C. Rahj

AU - Booker, Susan

AU - Wu, Li

AU - Hamilton, Stanley R.

AU - Sidransky, David

AU - Jen, Jin

PY - 1998/4/1

Y1 - 1998/4/1

N2 - We have searched for the presence of genetic alterations in serum DNA obtained from 44 colorectal cancer patients. Microsatellite analysis using highly polymorphic markers revealed loss of heterozygosity and/or microsatellite instability in 35 of 44 (80%) primary tumors. No alterations were detected in the paired serum DNA. We next used an oligonucleotide- mediated mismatch ligation assay to detect tumor specific gene mutations in the serum. Among the 16 cases with a K-ras gene mutation in the tumor, the same mutation was detected in three paired serum samples. In the 10 cases with a p53 mutation in the tumor, the identical mutation was detected in seven corresponding serum samples. Comparison of the molecular analysis with clinical diagnosis of these patients revealed that none of the seven Dukes' stage B patients with a K-ras mutation in their tumors demonstrated a mutation in the serum. In contrast, five of seven stage B patients with a p53 mutation in the tumor demonstrated a mutation in the paired serum (P = 0.01, Fisher's exact test). Taken together, either a K-ras or p53 mutation was detected in the serum in 40% of the 25 patients (95% confidence interval, 21- 61%), whose primary tumors contained a mutation and in 23% of the 44 patients (95% confidence interval, 12-38%) with colorectal cancer. The frequent detection of p53 mutation in the serum of patients with early stage tumors suggests a possible use of this approach for clinical prognosis and cancer monitoring of colorectal cancer patients.

AB - We have searched for the presence of genetic alterations in serum DNA obtained from 44 colorectal cancer patients. Microsatellite analysis using highly polymorphic markers revealed loss of heterozygosity and/or microsatellite instability in 35 of 44 (80%) primary tumors. No alterations were detected in the paired serum DNA. We next used an oligonucleotide- mediated mismatch ligation assay to detect tumor specific gene mutations in the serum. Among the 16 cases with a K-ras gene mutation in the tumor, the same mutation was detected in three paired serum samples. In the 10 cases with a p53 mutation in the tumor, the identical mutation was detected in seven corresponding serum samples. Comparison of the molecular analysis with clinical diagnosis of these patients revealed that none of the seven Dukes' stage B patients with a K-ras mutation in their tumors demonstrated a mutation in the serum. In contrast, five of seven stage B patients with a p53 mutation in the tumor demonstrated a mutation in the paired serum (P = 0.01, Fisher's exact test). Taken together, either a K-ras or p53 mutation was detected in the serum in 40% of the 25 patients (95% confidence interval, 21- 61%), whose primary tumors contained a mutation and in 23% of the 44 patients (95% confidence interval, 12-38%) with colorectal cancer. The frequent detection of p53 mutation in the serum of patients with early stage tumors suggests a possible use of this approach for clinical prognosis and cancer monitoring of colorectal cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0032053604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032053604&partnerID=8YFLogxK

M3 - Article

C2 - 9537240

AN - SCOPUS:0032053604

VL - 58

SP - 1405

EP - 1407

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -